Modeling human pediatric and adult gliomas in immunocompetent mice through costimulatory blockade

References

• McNeill KA. Epidemiology of brain tumors. Neurol Clin. 2016;34(4):981–10. doi:10.1016/j.ncl.2016.06.014.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 2018;20(suppl_4):iv1–iv86. doi:10.1093/neuonc/noy131.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. Epub 2016 May 9. doi:10.1007/s00401-016-1545-1.
   PubMed Web of Science ®Google Scholar
• deSouza RM, Shaweis H, Han C, Sivasubramaniam V, Brazil L, Beaney R, Sadler G, Al-Sarraj S, Hampton T, Logan J, et al. Has the survival of patients with glioblastoma changed over the years? Br J Cancer. 2016;114(2):146–150. Epub Dec 15. doi:10.1038/bjc.2015.421.
   PubMed Web of Science ®Google Scholar
• Vanan MI, Eisenstat DD. DIPG in children – what can we learn from the past? Front Oncol. 2015;5:237. Epub 2015/ 11/12. doi: 10.3389/fonc.2015.00237. PubMed PMID: 26557503; PubMed Central PMCID: PMCPMC4617108.
   PubMed Web of Science ®Google Scholar
• Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, Baugh J, Chaney B, Hoffmann M, Lane A, Fuller C, Miles L, Hawkins C, et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG registries. J Clin Oncol. 2018;36(19):1963–1972. Epub 2018 May 10. doi:10.200/JCO.2017.75.9308.
   PubMed Web of Science ®Google Scholar
• Adhikaree J, Moreno-Vicente J, Kaur AP, Jackson AM, Patel PM. Resistance mechanisms and barriers to successful immunotherapy for treating glioblastoma. Cells. 2020;9(2):263. Epub 2020/ 01/25. doi: 10.3390/cells9020263. PubMed PMID: 31973059.
   PubMed Web of Science ®Google Scholar
• Miyauchi JT, Tsirka SE. Advances in immunotherapeutic research for glioma therapy. J Neurol. 2018;265(4):741–756. doi:10.1007/s00415-017-8695-5. Epub 2017 Dec 5
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998–1013. Epub 2014 Jul 15. doi:10.158/2159-8290.CD-14-0001.
   PubMed Web of Science ®Google Scholar
• da Hora CC, Schweiger MW, Wurdinger T, Tannous BA. Patient-derived glioma models: from patients to dish to animals. Cells. 2019;8(10):(pii):cells8101177. doi:10.3390/cells.
   PubMed Web of Science ®Google Scholar
• Wu W, Zhong S, Gong Y, Shan Y, Yuan L, Wang L, Chen J, Zhang Z. A new molecular probe: an NRP-1 targeting probe for the grading diagnosis of glioma in nude mice. Neurosci Lett. 2020;714:134617. Epub 2019 Nov 6. doi:10.1016/j.neulet.2019.134617.
   PubMed Web of Science ®Google Scholar
• Papachristodoulou A, Silginer M, Weller M, Schneider H, Hasenbach K, Janicot M, Roth P. Therapeutic targeting of TGFbeta ligands in glioblastoma using novel antisense oligonucleotides reduces the growth of experimental gliomas. Clin Cancer Res. 2019;25(23):7189–7201. Epub 2019 Sep 17. doi:10.1158/078-0432.CCR-17-3024.
   PubMed Web of Science ®Google Scholar
• Qin H, Janowski M, Pearl MS, Malysz-Cymborska I, Li S, Eberhart CG, Walczak P. Rabbit model of human gliomas: implications for intra-arterial drug delivery. PLoS One. 2017;12(1):e0169656. doi:10.1371/journal.pone. eCollection 2017
   PubMed Web of Science ®Google Scholar
• Tivnan A, Heilinger T, Lavelle EC, Prehn JH. Advances in immunotherapy for the treatment of glioblastoma. J Neurooncol. 2017;131(1):1–9. doi:10.1007/s11060-016-2299-2. Epub 2016 Oct 14
   PubMed Web of Science ®Google Scholar
• Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15(7):422–442. doi:10.1038/s41571-018-0003-5.
   PubMed Web of Science ®Google Scholar
• Garcia C, Dubois LG, Xavier AL, Geraldo LH, da Fonseca AC, Correia AH. The orthotopic xenotransplant of human glioblastoma successfully recapitulates glioblastoma-microenvironment interactions in a non-immunosuppressed mouse model. BMC Cancer. 2014;14(1):923. doi:10.1186/471-2407-14-923.
   PubMedGoogle Scholar
• Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7(2):118–130. doi:10.1038/nri2017.
   PubMed Web of Science ®Google Scholar
• De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized mice for the study of immuno-oncology. Trends Immunol. 2018;39(9):748–763. doi:10.1016/j.it.2018.07.001. Epub Aug 2
   PubMed Web of Science ®Google Scholar
• Korhonen R, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009;104(4):276–284. doi:10.1111/j.742-7843.2009.00375.x. Epub 2009 Feb 18
   PubMed Web of Science ®Google Scholar
• Adams AB, Ford ML, Larsen CP. Costimulation blockade in autoimmunity and transplantation: the CD28 pathway. J Immunol. 2016;197(6):2045–2050. doi:10.4049/jimmunol.1601135.
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):459–465. doi:10.1084/jem.182.2.459.
   PubMed Web of Science ®Google Scholar
• Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16(1):111–135. doi:10.1146/annurev.immunol.16.1.111.
   PubMedGoogle Scholar
• Graves SS, Stone D, Loretz C, Peterson L, McCune JS, Mielcarek M, Storb R. Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig. Transplantation. 2009;88(3):317–322. doi:10.1097/TP.0b013e3181ae285.
   PubMed Web of Science ®Google Scholar
• Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11(12):852–863. doi:10.1038/nri3108.
   PubMed Web of Science ®Google Scholar
• Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381(6581):434–438. doi:10.1038/381434a0.
   PubMed Web of Science ®Google Scholar
• Li S, Oh BC, Chu C, Arnold A, Jablonska A, Furtmuller GJ, Qin H-M, Boltze J, Magnus T, Ludewig P, et al. Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts. Brain. 2019;142(11):3456–3472. doi:10.1093/brain/awz275.
   PubMedGoogle Scholar
• Semenkow S, Li S, Kahlert UD, Raabe EH, Xu J, Arnold A, Janowski M, Oh BC, Brandacher G, Bulte JWM, et al. An immunocompetent mouse model of human glioblastoma. Oncotarget. 2017;8(37):61072–61082. eCollection 2017 Sep 22. doi:10.18632/oncotarget.7851.
   PubMedGoogle Scholar
• Kahlert UD, Suwala AK, Koch K, Natsumeda M, Orr BA, Hayashi M, Maciaczyk J, Eberhart CG. Pharmacologic Wnt inhibition reduces proliferation, survival, and clonogenicity of glioblastoma cells. J Neuropathol Exp Neurol. 2015;74(9):889–900. doi:10.1097/NEN.0000000000000227.
   PubMed Web of Science ®Google Scholar
• Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, et al. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med. 2018;215(1):141–157. Epub 2017 Dec 4. doi:10.1084/jem.20171046.
   PubMed Web of Science ®Google Scholar
• Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol. 2017;28(7):1457–1472. doi:10.093/annonc/mdx106.
   PubMed Web of Science ®Google Scholar
• Liu CC, Yu CF, Wang SC, Li HY, Lin CM, Wang HH, Abate C, Chiang C-S. Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor. BMC Cancer. 2019;19(1):473. doi:10.1186/s12885-019-5700-7.
   PubMedGoogle Scholar
• Lenting K, Verhaak R, Ter Laan M, Wesseling P, Leenders W. Glioma: experimental models and reality. Acta Neuropathol. 2017;133(2):263–282. doi:10.1007/s00401-017-1671-4. Epub 2017 Jan 10
   PubMed Web of Science ®Google Scholar
• Stylli SS, Luwor RB, Ware TM, Tan F, Kaye AH. Mouse models of glioma. J Clin Neurosci. 2015;22(4):619–626. doi:10.1016/j.jocn.2014.10.013. Epub 5 Feb 16
   PubMed Web of Science ®Google Scholar
• Oh T, Fakurnejad S, Sayegh ET, Clark AJ, Ivan ME, Sun MZ, Safaee M, Bloch O, James CD, Parsa AT, et al. Immunocompetent murine models for the study of glioblastoma immunotherapy. J Transl Med. 2014;12:107. doi:10.1186/479-5876-12-107.
   PubMed Web of Science ®Google Scholar
• Misuraca KL, Hu G, Barton KL, Chung A, Becher OJ. A novel mouse model of diffuse intrinsic pontine glioma initiated in Pax3-expressing cells. Neoplasia. 2016;18(1):60–70. doi:10.1016/j.neo.2015.12.002.
   PubMed Web of Science ®Google Scholar
• Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5):391–403. doi:10.1016/j.ccr.2006.03.030.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xiao A, diPierro CG, Carpenter JE, Abdel-Fattah R, Redpath GT, Lopes MBS, Hussaini IM. An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9. Am J Pathol. 2010;176(6):3032–3049. doi:10.2353/ajpath.010.090571. Epub 2010 Apr 22
   PubMed Web of Science ®Google Scholar
• Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, Kelly JJ, Nguyen SA, Chan JA, Weljie AM, Cairncross JG, et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol. 2012;14(2):184–191. Epub 2011 Dec 13. doi:10.1093/neuonc/nor207.
   PubMed Web of Science ®Google Scholar
• Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer. 2014;14(2):92–107. doi:10.1038/nrc3655.
   PubMed Web of Science ®Google Scholar
• Noorani I. Genetically engineered mouse models of gliomas: technological developments for translational discoveries. Cancers (Basel). 2019;11(9):(pii):cancers11091335. doi:10.3390/cancers.
   PubMed Web of Science ®Google Scholar
• Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, et al. Antitumor effect of programmed death-1 (PD-1) blockade in humanized the NOG-MHC double knockout mouse. Clin Cancer Res. 2017;23(1):149–158. Epub 2016 Jul 25. doi:10.1158/078-0432.CCR-16-122.
   PubMed Web of Science ®Google Scholar
• Suematsu S, Watanabe T. Generation of a synthetic lymphoid tissue-like organoid in mice. Nat Biotechnol. 2004;22(12):1539–1545. doi:10.038/nbt039. Epub 2004 Nov 28
   PubMed Web of Science ®Google Scholar
• Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174(10):6477–6489. doi:10.4049/jimmunol.174.10.6477.
   PubMed Web of Science ®Google Scholar
• Nagai S, Azuma M. The CD28-B7 family of co-signaling molecules. Adv Exp Med Biol. 2019;1189:25–51. doi:10.1007/978-981-32-9717-3_2.
   PubMed Web of Science ®Google Scholar
• Alegre ML, Fallarino F. Mechanisms of CTLA-4-Ig in tolerance induction. Curr Pharm Des. 2006;12(2):149–160. doi:10.2174/138161206775193046.
   PubMed Web of Science ®Google Scholar
• Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174(3):561–569. doi:10.1084/jem.174.3.561.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wilson JM. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science. 1996;273(5283):1862–1864. doi:10.126/science.273.5283.1862.
   PubMed Web of Science ®Google Scholar
• Grewal IS, Foellmer HG, Grewal KD, Xu J, Hardardottir F, Baron JL, Janeway CA, Flavell RA. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science. 1996;273(5283):1864–1867. doi:10.126/science.273.5283.1864.
   PubMed Web of Science ®Google Scholar
• Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L. Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med. 1992;175(4):1091–1101. doi:10.84/jem.175.4.
   PubMed Web of Science ®Google Scholar
• Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help. J Immunol. 1992;149:3817–3826.
   PubMed Web of Science ®Google Scholar
• Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH, Knechtle SJ, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997;94(16):8789–8794. doi:10.1073/pnas.94.16.8789.
   PubMed Web of Science ®Google Scholar
• Lehnert AM, Mottram PL, Han W, Walters SN, Patel AT, Hawthorne WJ, Cowan PJ, d'Apice AJ, O'Connell PJ. Blockade of the CD28 and CD40 pathways result in the acceptance of pig and rat islet xenografts but not rat cardiac grafts in mice. Transpl Immunol. 2001;9(1):51–56. doi:10.1016/s0966-3274(01)00040-5.
   PubMed Web of Science ®Google Scholar
• Wu J, Hu M, Qian YW, Hawthorne WJ, Burns H, Liuwantara D, Alexander SI, Yi S, O’Connell PJ. In vivo costimulation blockade-induced regulatory T cells demonstrate dominant and specific tolerance to porcine islet xenografts. Transplantation. 2017;101(7):1587–1599. doi:10.097/TP.0000000000001482.
   PubMed Web of Science ®Google Scholar
• Srinivas NR, Shyu WC, Weiner RS, Tay LK, Greene DS, Barbhaiya RH. Pharmacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following intravenous and subcutaneous administration to mice. J Pharm Sci. 1995;84(12):1488–1489. doi:10.002/jps.2600841217.
   PubMed Web of Science ®Google Scholar
• Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med. 1993;178(5):1567–1575. doi:10.084/jem.178.5.
   PubMed Web of Science ®Google Scholar
• Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci. 2017;20(2):136–144. doi:10.1038/nn.4475. Epub 2017 Jan 16
   PubMed Web of Science ®Google Scholar
• Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014;128(4):573–581. doi:10.1007/s00401-014-1319-6. Epub 2014 Jul 22
   PubMed Web of Science ®Google Scholar
• Cordero FJ, Huang Z, Grenier C, He X, Hu G, McLendon RE. Histone H3.3K27M Represses p16 to accelerate gliomagenesis in a murine model of DIPG. Mol Cancer Res. 2017;15(9):1243–1254. Epub 2017 May 18. doi:10.158/541-7786.MCR-16-0389.
   PubMed Web of Science ®Google Scholar
• Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meer H, Westphal M, Lamszus K, et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2008;27(20):2897–2909. Epub 2007 Nov 26. doi:10.1038/sj.onc.1210949.
   PubMed Web of Science ®Google Scholar
• Koschmann C, Calinescu -A-A, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, Mendez F, Kamran N, Dzaman M, Mulpuri L, et al. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci Transl Med. 2016;8(328):328ra28. doi:10.1126/scitranslmed.aac8228.
   PubMed Web of Science ®Google Scholar
• Oldrini B, Curiel-Garcia A, Marques C, Matia V, Uluckan O, Grana-Castro O, Torres-Ruiz R, Rodriguez-Perales S, Huse JT, Squatrito M, et al. Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. Nat Commun. 2018;9(1):1466. doi:10.038/s41467-018-03731-w.
   PubMedGoogle Scholar
• Funato K, Major T, Lewis PW, Allis CD, Tabar V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science. 2014;346(6216):1529–1533. doi:10.126/science.1253799. Epub 2014 Nov 20
   PubMed Web of Science ®Google Scholar
• Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006;1(1):97–117. doi:10.1146/annurev.pathol.1.110304.00043.
   PubMed Web of Science ®Google Scholar
• Das S, Marsden PA. Angiogenesis in glioblastoma. N Engl J Med. 2013;369(16):1561–1563. doi:10.056/NEJMcibr1309402.
   PubMed Web of Science ®Google Scholar
• Li A, Walling J, Kotliarov Y, Center A, Steed ME, Ahn SJ. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res. 2008;6(1):21–30. Epub 2008 Jan 9. doi:10.1158/541-7786.MCR-07-0280.
   PubMed Web of Science ®Google Scholar